Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zelboraf And Yervoy Benefit From Secret Discounts To Pass NICE Barrier

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE has recommended Roche’s Zelboraf and BMS’ Yervoy, as expected based partly on undeniable life extension capabilities, but also on secret price discounts offered by both manufacturers.

You may also be interested in...



NICE Yervoy, Invokana Rulings Show Need for Regulator/HTA Dialogue

NICE downgrades BMS’ Yervoy, while Janssen omits filing for all combinations for Invokana, underscoring the need for EU harmonization through HTA/regulator dialogue.

Zelboraf Pricing In Germany Still Tied Up By Crossover Trial Design

IQWiG reiterates its “considerable added benefit” rating for the melanoma drug, but pricing negotiations will reopen in 2014.

NICE Proves Cost Is Not Everything, Clears Two High-Priced Skin Cancer Drugs

Roche’s Zelboraf and Bristol-Myers Squibb’s Yervoy exceed NICE’s cost-effectiveness limit, but are still waved through as targeting unmet medical need.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel